Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEP503 with Chemoradiotherapy in Rectal Cancer
NCT02465593Phase 2Terminated
- Sponsor
- PharmaEngine, Inc.
- Start
- Jun 2015
- Primary completion
- Jul 2021
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of NBTXR3 in rectal cancer, sponsored by PharmaEngine, Inc. Primary endpoints: Dose Limiting Toxicity up to 36 months, Recommended Injection Volume up to 36 months and 1 more. Started Jun 2015; status: terminated.
02
Drugs
NBTXR3
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT02465593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02465593.